Comparative Outcomes of Meropenem-Vaborbactam vs. Ceftazidime-Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021.

ABSTRACT: Background/Objectives: Meropenem-vaborbactam (MEV) and ceftazidime-avibactam (CZA) are active against "urgent threat" pathogens like carbapenem-resistant Enterobacterales (CRE). However, few studies have compared outcomes between them. Methods: To explore comparative outcomes of MEV vs. CZA, we conducted a multicenter retrospective cohort study of all adult hospitalized patients with a serious infection (sepsis, urinary tract infection [UTI], complicated intraabdominal [cIAI] infection, or pneumonia) within the PINC AI Database, 2019-2021. Descriptive statistics compared the two groups along demographic and clinical characteristics, and multiple regression derived adjusted outcomes. Results: Among 1,989,765 patients who met enrollment criteria, 455 received MEV and 232

SUBMITTER: Zilberberg MD 

PROVIDER: S-EPMC11762528 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature